NCT06189391View on ClinicalTrials.gov

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

March 31, 2027

Study Completion Date

March 30, 2029

Conditions
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
DRUG

MK-1045

IV infusion

Trial Locations (11)

100071

RECRUITING

Fifth Medical Center of PLA General Hospital ( Site 0005), Beijing

100142

RECRUITING

Beijing Cancer hospital ( Site 0001), Beijing

200120

RECRUITING

Shanghai East Hospital ( Site 0002), Shanghai

250117

ACTIVE_NOT_RECRUITING

Shandong Cancer Hospital ( Site 0008), Jinan

300060

ACTIVE_NOT_RECRUITING

Tianjin Medical University Cancer Institute and Hospital ( Site 0010), Tianjinc

330029

RECRUITING

Jiangxi Cancer Hospital ( Site 0007), Nanchang

361000

RECRUITING

The First Affiliated Hospital of Xiamen University ( Site 0011), Xiameng

450000

RECRUITING

Henan Cancer Hospital ( Site 0009), Zhengzhou

451161

RECRUITING

The First Affiliated Hospital of Zhengzhou University ( Site 0006), Zhengzhou

510060

RECRUITING

Sun Yat-Sen University Cancer Center ( Site 0003), Guangzhou

050035

RECRUITING

The Fourth Hospital of Hebei Medical University. ( Site 0004), Shijiazhuang

All Listed Sponsors
lead

MSD R&D (China) Co., Ltd.

INDUSTRY